Abstract
Liposomes are utilised as a delivery carrier in insulin therapy for several
reasons; an enhancement in the oral absorption of insulin, the ability to selectively target
insulin to the hepatic system, and prolong drug action for proper dose regimen. The
hepatocytic delivery of insulin can be achieved efficiently through the insulin liposomal
method. While treating diabetes with liver-targeted liposomes, it is expected that
constraints will arise due to the formulation being supplied by an intravenous route.
Furthermore, due to the dilute concentration of insulin in the liposomal formulation, the
overall cost of the liposomal insulin would rise. The consequence of encapsulating the
drug in the liposomal carrier is improved oral absorption of insulin. Drug action can be
continued by giving subcutaneous liposomal insulin. Insulin remains at the site of
injection, and the occurrence of a lipid matrix for subcutaneous insulin delivery raises
concerns about over-improved antigenicity. The liposomal insulin sustains the role of a
delivery system in understanding and treating diabetes using the hepatically targeted
liposomal system. This pharmacological aspect has highlighted the role of the liver in
the metabolic complications associated with diabetes mellitus.
Keywords: Diabetes, Hepatic, Insulin, Liposomes.